The clinical problem addressed in this proposed study is the need to prevent or reverse the process of inhibitor antibody formation in congenital and acquired hemophilia A patients. Although the number of affected patients is relatively small, development of inhibitor antibodies can result in life-threatening bleeding episodes, where the cost of treatment can exceed one million dollars per patient, per year. The experimental goals of this project are (1) to identify the predominant T-cell epitopes in human factor VIM(hFVIII), both in healthy individuals and in patients who have developed an allo- or auto-immune (""""""""inhibitor"""""""") response to hFVIII;(2) to characterize the cytokine profiles of the stimulated T cells (3) to describe the evolution of these T-cell epitopes in inhibitor patients over time;and (4) to modify these epitopes in peptides, in recombinant hFVIII domains, and in full-length hFVIII molecules by introducing point mutations. Our central hypothesis is that modification of T-cell epitopes in FVIII will lead to development of a less immunogenic """"""""next-generation"""""""" FVIII for use in cofactor replacement therapy. In addition, tolerance induction strategies with peptides or recombinant protein domains will be useful for patients who have already developed an inhibitor response to FVIII. Specifically, CD4+-enriched peripheral blood leukocytes will be isolated from hemophilia A patients as well as from healthy individuals, cultured, and stimulated with hFVIII, pools of synthetic peptides corresponding to the hFVIII domains, individual peptides, recombinant hFVIII domains, and proteolytic digests of hFVIII domains. Blood samples will be obtained from inhibitor patients at regular intervals and their T cells will be assayed. Immunodominant peptides, or possibly combinations of peptides, will be identified, their sequences will be modified, and the new peptides will be tested in the same manner. Promising mutations will then be introduced into the corresponding domains of a factor VIII protein, and the new proteins will be tested for both T-cell stimulation and for preservation of normal hFVIII function.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL081015-05
Application #
7922607
Study Section
Special Emphasis Panel (ZHL1)
Project Start
2009-09-01
Project End
2010-08-31
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
5
Fiscal Year
2009
Total Cost
$422,138
Indirect Cost
Name
Puget Sound Blood Center
Department
Type
DUNS #
092881085
City
Seattle
State
WA
Country
United States
Zip Code
98104
Slichter, Sherrill J; Corson, Jill; Jones, Mary Kay et al. (2014) Exploratory studies of extended storage of apheresis platelets in a platelet additive solution (PAS). Blood 123:271-80
Slichter, Sherrill J; Bolgiano, Doug; Corson, Jill et al. (2014) Extended storage of buffy coat platelet concentrates in plasma or a platelet additive solution. Transfusion 54:2283-91
Slichter, S J; Bolgiano, D; Corson, J et al. (2013) Extended storage of autologous apheresis platelets in plasma. Vox Sang 104:324-30
Slichter, Sherrill J; Corson, Jill; Jones, Mary Kay et al. (2012) Platelet concentrates prepared after a 20- to 24-hour hold of the whole blood at 22°C. Transfusion 52:2043-8
Wang, Wenjing; Gilligan, Diana M; Sun, Sijie et al. (2011) Distinct functional effects for dynamin 3 during megakaryocytopoiesis. Stem Cells Dev 20:2139-51
Slichter, Sherrill J; Bolgiano, Doug; Corson, Jill et al. (2010) Extended storage of platelet-rich plasma-prepared platelet concentrates in plasma or Plasmalyte. Transfusion 50:2199-209
Reems, Jo-Anna; Pineault, Nicolas; Sun, Sijie (2010) In vitro megakaryocyte production and platelet biogenesis: state of the art. Transfus Med Rev 24:33-43
Slichter, Sherrill J; Christoffel, Todd; Corson, Jill et al. (2009) Effects of pretransfusion warming of platelets to 35 degrees C on posttransfusion platelet viability. Transfusion 49:2319-25
Lannutti, Brian J; Epp, Angela; Roy, Jacqueline et al. (2009) Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis. Blood 113:1778-85
Reems, Jo-Anna; Wang, Wenjing; Tsubata, Ken et al. (2008) Dynamin 3 participates in the growth and development of megakaryocytes. Exp Hematol 36:1714-27